Skip to main content
. 2020 Nov 23;12(11):3486. doi: 10.3390/cancers12113486

Figure 3.

Figure 3

Survival outcomes of melanoma patients that ceased anti-PD1 immunotherapy. Kaplan–Meier probability curves for progression-free survival (PFS, A) and overall survival (OS, B) for the total cohort of patients who discontinued treatment in the absence of disease progression (median PFS and OS not yet reached. (C) Dichotomised treatment-free survival (TFS) of patients detectable or undetectable ctDNA at cessation (p < 0.001, log-rank test, median TFS not yet reached).